- Pfizer Inc PFE reported Q1 sales of $14.6 billion up 45% Y/Y, beating a consensus of $13.6 billion. It saw a 3% favorable impact of foreign exchange.
- Excluding the sales from COVID-19 vaccine (BNT162b2) of $3.5 Billion, overall revenues increased 8% operationally, including a 5% negative impact from the pricing.
- Pfizer's growth was driven by higher sales from BNT162b2, Eliquis (+25%), Vyndaqel/Vyndamax (+88%), Xeljanz (+18%), Xtandi (+28%), Inlyta (+34%); as well as Biosimilars, which grew 79% operationally to $530 million and Hospital products, which grew 10% to $2.3 billion.
- Adjusted EPS of $0.93 grew 47% Y/Y and beat the consensus of $0.78. Reported EPS increased 44% to $0.86.
- Dividend: Pfizer maintained its quarterly dividend at $0.39/share and not reduce due to the initiation of a quarterly dividend by Viatris Inc.
- Guidance: Pfizer estimates COVID-19 vaccine revenue of roughly $26 billion versus $15 billion estimated earlier. It includes 1.6 billion doses that are expected to be delivered in 2021 under contracts that have been signed through mid-April 2021.
- It raised the FY21 revenue outlook to $70.5 billion to $72.5 billion from $59.4 to $61.4 billion prior, higher than the consensus of around $63 billion.
- The company anticipates adjusted EPS of $3.55 to $3.65 compared to prior guidance of $3.10 to $3.20, beating the consensus of $3.36.
- Pfizer also said it is working on a new formulation of the COVID-19 vaccine that could be stored at standard refrigerator temperatures for up to 10 weeks.
- Price Action: PFE shares are up 1.4% at $40.37 in the premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
